drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified T cells)
drug_description
Autologous T lymphocytes genetically modified ex vivo (typically via retroviral or lentiviral vectors) to express a chimeric antigen receptor targeting tumor antigens; adoptively transferred for durable in vivo persistence and anti-cancer activity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically modified ex vivo (commonly via retroviral or lentiviral vectors) to express a chimeric antigen receptor that binds tumor surface antigens independent of MHC; CAR signaling (CD3ΞΆ with costimulatory domains such as CD28 or 4-1BB) activates T cells to proliferate, persist, release cytokines, and mediate cytotoxic killing of tumor cells.
drug_name
Chimeric Antigen Receptor (CAR) T cells
nct_id_drug_ref
NCT05713214